It seems to have begun in Norway, the international pressure to switch patients from well-known brand biologic agents, such as Remicade (infliximab), to biosimilar agents, due to a significant cost advantage.1 This biosimilar came with a 39% price markdown last year compared with the brand, and when Norway called for bids, the discount went to…
Brodalumab, an interleukin (IL) 17 inhibitor, is currently in early clinical trials (Phase 1b and Phase 2) for a number of different autoimmune diseases.1 Amgen recently terminated its co-development and commercialization agreement with AstraZeneca for the brodalumab investigational program in trials for moderate to severe plaque psoriasis, psoriatic arthritis and axial spondyloarthritis. Amgen’s decision to…
As the literature on comorbidities linked to psoriatic arthritis (PsA) expands, it’s becoming more difficult for clinicians to keep up with what comorbidities should be assessed and how these comorbidities affect treatment selection. Given this, rheumatologists at the Perelman School of Medicine at University of Pennsylvania, Cleveland Clinic and Hospital for Special Surgery in New…
Clinical manifestations, approaches to diagnosis, treatment
Recommendations on diagnosing, treating health conditions that cross over both specialties
Patients often manage their condition better, perform daily activities with more ease with help from therapists
A 65-year-old man presents with symptoms of erythrodermic psoriasis flare
Plus, rheumatology drug news from EULAR 2014
Rheumatologists at the California Rheumatology Alliance 10th Annual Medical & Scientific Meeting discuss challenges to diagnosing, managing spondyloarthritides
Legislative news on biosimilars, safety warning on epidural corticosteroid injections, and other drug updates rheumatologists need to know